Lynda Roman, MD
Gynecologic Oncology · Pasadena, CANPI 1386649713
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,713 of the $5,313 with a category attached, or 88.7%. GSK accounts for 91.4% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $4,743, more than ten times the $227 reported in 2019.
Across 13 payments — averaging $408.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$5K
- Seagen Inc.$122
- Takeda Pharmaceuticals U.S.A., Inc.$119
- Intuitive Surgical$108
- Immunogen, Inc.$61
- Guard Medical Inc.$33
- plus $16 from 1 others
Across 18 payments — averaging $4062.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$73K
What the payments were for
- Consulting fees$4,71389%
- Food & beverage$53610%
- Education$651%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 6 | $4,855 |
| Seagen Inc. | 1 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $119 |
| Intuitive Surgical | 1 | $108 |
| Immunogen, Inc. | 1 | $61 |
| Guard Medical Inc. | 2 | $33 |
| Myriad Genetic Laboratories, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JEMPERLI$4,713
- ADCETRIS$122
- Da Vinci Surgical System$108
How this compares
$5,313 in reported general payments places this provider in the 70th percentile of 152 gynecologic oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 12 | $203,791 |
| Everolimus | 24 | $154,909 |
| EliquisApixaban | 13 | $9,060 |
| Estradiol | 28 | $1,601 |
| Estradiol (Twice Weekly)Estradiol | 15 | $794 |
| Ondansetron Hcl | 13 | $675 |
| Sodium ChlorideSodium Chloride 0.45 % | 28 | $462 |
| Letrozole | 15 | $461 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Pasadena
- John ChanSan Francisco$2M
- Dana ChaseLos Angeles$1.3M
- Ramez EskanderEncinitas$706K
- Krishnansu TewariOrange$495K
- Fabio CappucciniOrange$313K
- Mehdi Moslemi-KebriaUpland$225K
- Amer KaramStanford$168K
- Rebecca BrooksSacramento$133K
- Kenneth KimWest Hollywood$88K
- Oliver DorigoStanford$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.